Lung Cancer Update
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.
Latest episodes
Jun 20, 2025 • 1h 58min
EGFR Mutation-Positive Non-Small Cell Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting
Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi Jänne, Dr Suresh Ramalingam, Dr Joshua Sabari and moderator Dr Helena Yu present data informing treatment decision-making for EGFR-mutated NSCLC at the 2025 ASCO annual meeting. CME information and select publications here.
Jun 10, 2025 • 58min
Non-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and Advances
Dr Jessica J Lin from Massachusetts General Hospital in Boston and Dr Joel W Neal from Stanford Cancer Institute in California summarize major treatment advances over the past year and review relevant ongoing clinical trials using targeted therapies for patients with non-small cell lung cancer. CME information and select publications here.
May 18, 2025 • 50min
Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit
Ram Govindan, a clinical investigator from Washington University specializing in non-small cell lung cancer, joins Stephen Liu from Georgetown University, who focuses on innovative immunotherapy treatments. They discuss groundbreaking advancements in combining chemotherapy with immunotherapy, showing improved survival rates. The conversation highlights the potential of bispecific therapies and antibody-drug conjugates, as well as the role of biomarkers in personalizing treatment. They also touch on emerging strategies like TDXD for HER2 mutations, shaping the future of lung cancer therapy.
Apr 30, 2025 • 52min
EGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology Summit
Clinical investigators discuss available data guiding the management of EGFR mutation-positive non-small cell lung cancer. CME information and select publications here.
Apr 26, 2025 • 1h 33min
For Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress
Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.
Apr 10, 2025 • 57min
First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor
Dr. Justin F Gainor, a medical oncologist from Massachusetts General Hospital, delves into groundbreaking treatments for ALK-positive metastatic non-small cell lung cancer. He discusses the effectiveness of ALK inhibitors, exploring strategies for optimizing treatments and identifying exceptional responders. The conversation highlights the complexities of managing young patients, including family planning and the implications of various therapies. Gainor also addresses the importance of monitoring CNS effects, weight gain challenges, and innovative approaches to treatment resistance.
Feb 6, 2025 • 1h
EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
Dr Enriqueta Felip from the Vall d’Hebron Institute of Oncology in Barcelona, Spain, and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging treatment approaches for patients with EGFR-mutant non-small cell lung cancer. CME information and select publications here
Dec 13, 2024 • 48min
Cases from the Community: Integrating New Research Findings into Current Practice — Lung Cancer
Dr Edward B Garon shares his perspectives on the evolving therapeutic landscape for patients with lung cancer.
Dec 11, 2024 • 59min
Meet The Professor: Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer
Dr Heather Wakelee from Stanford University School of Medicine in California discusses the implications of recent datasets for the current and future use of nontargeted therapy for metastatic non-small cell lung cancer.
Nov 25, 2024 • 1h
The Implications of Recent Datasets for the Current and Future Management of Lung Cancer — A Review of Information from ESMO Congress 2024 and Other Conferences
Dr Suresh S Ramalingam from the Emory University School of Medicine in Atlanta, Georgia and Dr Gregory J Riely from Memorial Sloan Kettering Cancer Center in New York, New York discuss the implications of recent data sets for the current and future management of lung cancer.
